Reciprocal changes in serum albumin and alpha-fetoprotein levels in the recovery course of acute viral hepatitis stimulated by glucagon and insulin therapy: Analysis of a double blind controlled trial

1989 ◽  
Vol 24 (2) ◽  
pp. 143-148 ◽  
Author(s):  
Kenji Fujiwara ◽  
Itsuro Ogata ◽  
Hiroshi Oka
Keyword(s):  
Serum Albumin ◽  
Insulin Therapy ◽  
Viral Hepatitis ◽  
Acute Viral Hepatitis ◽  
Controlled Trial ◽  
Alpha Fetoprotein ◽  
Double Blind ◽  
Glucagon And Insulin

A multi-centre double-blind controlled trial of glucagon and insulin therapy for severe acute hepatitis

1989 ◽  
Vol 24 (3) ◽  
pp. 332-336 ◽  
Author(s):  
Hiroshi Oka ◽  
Kenji Fujiwara ◽  
Kiwamu Okita ◽  
Hiromasa Ishii ◽  
Akira Sakuma
Keyword(s):  
Insulin Therapy ◽  
Acute Hepatitis ◽  
Controlled Trial ◽  
Double Blind ◽  
Severe Acute Hepatitis ◽  
Glucagon And Insulin

Are increases in thyroxin-binding globulin in patients with acute hepatitis ascribable to synthesis by regenerating hepatocytes?

1988 ◽  
Vol 34 (4) ◽  
pp. 776-780 ◽  
Author(s):  
C Shigemasa ◽  
T Tanaka ◽  
Y Mitani ◽  
Y Ueta ◽  
S Taniguchi ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Serum Albumin ◽  
Acute Hepatitis ◽  
Viral Hepatitis ◽  
Acute Viral Hepatitis ◽  
Normal Subjects ◽  
Reference Intervals ◽  
Hospitalized Patients ◽  
Serum T4 ◽  
Expected Increase

Abstract We describe a case of liver cirrhosis lacking the expected increase in serum thyroxin (T4)-binding globulin (TBG) despite abrupt, severe increases in aspartate and alanine aminotransferases (ASAT and ALAT) in serum. Sequential change in serum T4, triiodothyronine (T3), and TBG concentrations were also measured retrospectively in serum of 10 hospitalized patients with acute viral hepatitis. Although their mean T4 and TBG concentrations significantly exceeded those in 40 normal subjects (P less than 0.002 and P less than 0.001, respectively), these values were within the normal reference intervals in five patients. ASAT and ALAT concentrations were not significantly different in patients with increased TBG and patients with normal TBG, whereas mean concentrations of serum albumin and cholinesterase and mean prothrombin times (in percent) in the former group were significantly higher than those in the latter group (P less than 0.05, P less than 0.05, and P less than 0.001, respectively). For 60 samples with increased ASAT and ALAT, TBG and albumin or cholinesterase correlated significantly (r = 0.49, P less than 0.001 and r = 0.50, P less than 0.001, respectively), but not TBG and ASAT or ALAT. Collectively, these results suggest that the increase in serum TBG in acute hepatitis may reflect its synthesis in regenerating hepatocytes rather than a simple leakage from damaged hepatocytes.

(+)-Cyanidanol-3 in the Treatment of Acute Viral Hepatitis: A Randomized Controlled Trial

Hepatology ◽  
1984 ◽  
Vol 4 (2) ◽  
pp. 331-335 ◽  
Author(s):  
Hans Schomerus ◽  
Karl H. Wiedmann ◽  
Wolfgang Dölle ◽  
Herrmann Peerenboom ◽  
Georg Strohmeyer ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Viral Hepatitis ◽  
Hepatitis A ◽  
Acute Viral Hepatitis ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Viral Hepatitis A ◽  
Acute Viral Hepatitis A

scholarly journals Controlled trial of corticosteroid therapy in severe acute viral hepatitis

1978 ◽  
Vol 75 (5) ◽  
pp. 992
Author(s):  
A. Ware ◽  
J. Cuthbert ◽  
E. Elgenbrodt ◽  
J. Shorey ◽  
B. Combes
Keyword(s):  
Viral Hepatitis ◽  
Corticosteroid Therapy ◽  
Acute Viral Hepatitis ◽  
Controlled Trial

scholarly journals The Effect of Myo-inositol Supplementation on the Prevention of Gestational Diabetes in Overweight Pregnant Women: a Randomized, Double-blind, Controlled Trial

2021 ◽  
Author(s):  
Sedighe Esmaeilzadeh ◽  
Reza Ghadimi ◽  
Sepideh Mashayekhamiri ◽  
Mouloud Agajani Delavar ◽  
Zahra Basirat
Keyword(s):  
Folic Acid ◽  
Gestational Diabetes ◽  
Insulin Therapy ◽  
Pregnant Women ◽  
Controlled Trial ◽  
Daily Intake ◽  
Control Group ◽  
Oral Glucose ◽  
Number Needed To Treat ◽  
Double Blind

Abstract Purpose: This study is striving to test the hypothesis that a low dosage of myo-inositol supplementation may decrease the likelihood of gestational diabetes in overweight, pregnant women. Methods: A randomized, double-blind, controlled trial was performed on 60 eligible overweight, pregnant women at 12-14 weeks of gestation at two Iranian obstetric clinics. The participants were divided into two groups based on blocked randomization. The myo-inositol group, receiving 2000 mg plus 200 μg folic acid daily and the control group, receiving 400 μg of folic acid daily from 14 - 24 gestational weeks. The occurrence of gestational diabetes was determined based on 75-g 2-hour oral glucose tolerance test (OGTT) at 24–28 gestational weeks, which was the primary outcome of the study. The secondary outcomes were: the evaluation of insulin therapy, insulin resistance, and lipid profile, gestational weight gain, as well as fetal and maternal outcomes. Results: The incidence of gestational diabetes in myo-inositol group was noticeably minimized compared with that of the control group (RR 0.29, 95% CI 0.09-0.94, p= 0.037). There were no differences between the two groups in terms of fasting blood sugar, fasting insulin, HOMA-IR, insulin therapy, and triglyceride. There was no report of severe adverse drug reactions, either.Conclusions: The absolute risk reduction and the ‘‘Number-Needed-to-Treat’’ for gestational diabetes were 26.8% (95% CI, 5.6–48) and 3.7 (95% CI, 2.1–18.0), respectively. Hence, it can be concluded that approximately one out of every four overweight pregnant women receiving myo-inositol benefitted from its daily intake.

Sign in / Sign up

Export Citation Format

Share Document